CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease

Journal of Clinical Investigation

Volumn 127, Issue 7, 2017, Pages 2719-2724

  Yang, Su ^a   Chang, Renbao ^a,b,c   Yang, Huiming ^a   Zhao, Ting ^a   Hong, Yan ^a   Kong, Ha Eun ^a   Sun, Xiaobo ^d   Qin, Zhaohui ^d   Jin, Peng ^a   Li, Shihua ^a   Li, Xiao Jiang ^a,e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d EMORY UNIVERSITY   (United States)

^e JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CORPUS STRIATUM; CRISPR CAS SYSTEM; GENE EDITING; GENE EXPRESSION REGULATION; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; MOUSE; NERVE CELL; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; ALLELE; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; GENETICS; HEK293 CELL LINE; HUMAN; HUNTINGTON DISEASE; METABOLISM; MUTANT MOUSE STRAIN;

HTT PROTEIN, MOUSE; HUNTINGTIN; PEPTIDE; POLYGLUTAMINE;

ALLELES; ANIMALS; CRISPR-CAS SYSTEMS; DISEASE MODELS, ANIMAL; GENE EDITING; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; MICE; MICE, MUTANT STRAINS; PEPTIDES;

EID: 85021725683     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI92087     Document Type: Article

References (21)

1. Bates GP, et al. Huntington disease. Nat Rev Dis Primers. 2015;1:15005.
2. Carroll JB, et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/ allele-specific silencing of mutant huntingtin. Mol Ther. 2011;19(12):2178-2185.
3. Drouet V, et al. Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells. PLoS One. 2014;9(6):e99341.
4. Monteys AM, Ebanks SA, Keiser MS, Davidson BL. CRISPR/Cas9 editing of the mutant huntingtin allele in vitro and in vivo. Mol Ther. 2017;25(1):12-23.
5. Harper SQ, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A. 2005;102(16):5820-5825.
6. Rodriguez-Lebron E, Paulson HL. Allele-specific RNA interference for neurological disease. Gene Ther. 2006;13(6):576-581.
7. Wang G, Liu X, Gaertig MA, Li S, Li XJ. Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc Natl Acad Sci U S A. 2016;113(12):3359-3364.
8. Liu X, et al. N-terminal huntingtin knock-in mice: implications of removing the N-terminal region of huntingtin for therapy. PLoS Genet. 2016;12(5):e1006083.
9. Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol. 2003;465(1):11-26.
10. Wheeler VC, et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet. 2000;9(4):503-513.
11. Lin CH, et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet. 2001;10(2):137-144.
12. Menalled LB, et al. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J Neurosci. 2002;22(18):8266-8276.
13. Swiech L, et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol. 2015;33(1):102-106.
14. Pépin J, et al. In vivo imaging of brain glutamate defects in a knock-in mouse model of Huntington's disease. Neuroimage. 2016;139:53-64.
15. Palfi S, et al. Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates. Mol Ther. 2007;15(8):1444-1451.
16. Yu ZX, Li SH, Evans J, Pillarisetti A, Li H, Li XJ. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J Neurosci. 2003;23(6):2193-2202.
17. Hickey MA, et al. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience. 2008;157(1):280-295.
18. Veres A, et al. Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell. 2014;15(1):27-30.
19. Iyer V, et al. Off-target mutations are rare in Cas9-modified mice. Nat Methods. 2015;12(6):479.
20. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell. 2000;101(1):57-66.
21. DiFiglia M, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A. 2007;104(43):17204-17209.